Cite

Copy

Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

Management of Supratentorial Choroid Plexus Tumors in Children

This page was last updated on April 8th, 2024

Initial Management at Presentation

  • Control of hydrocephalus: Emergent management of hydrocephalus may be required if the child is lethargic from elevated ICP related to hydrocephalus. EVD placement may be required prior to definitive resection of the tumor.
  • Embolization: Preoperative embolization is useful in reducing the amount of blood loss during the surgical resection. However, since 75% of these tumors are diagnosed in children younger than 2 years of age, there are technical difficulties linked to embolization, and the risks vs. benefits might differ depending on the experience of the interventional team.
  • Surgical resection: For choroid plexus papillomas, total surgical resection leads to a cure in a large percentage of cases and therefore should be the aim. For choroid plexus carcinomas, gross total resection also leads to better outcomes.

Adjunctive Therapies

Choroid plexus carcinoma

  • Chemotherapy: The role of adjuvant chemotherapy is controversial. It can be used in young children when deferring radiation treatment. Use of a combination of ifosfamide, carboplatin, and etoposide (ICE) has been described (111).
  • Radiotherapy: As many as 44% of carcinomas will have CSF seeding. Radiotherapy is indicated with a positive neuraxis staging, a WHO grade III, and positive margins. However, radiation treatment will be deferred in children younger than 3 or 4 years of age (111).

Follow-up

  • Scheduled follow-up: Typically, early follow-up is planned for 4–6 weeks after surgery.
  • Postoperative imaging important: The first postoperative imaging should be done within 72 hours to make sure there is no residual tumor or to assess its size if tumor remains. Follow-up imaging will then depend on the pathology of the tumor and on the adjuvant therapies (typically every 3 months for choroid plexus carcinomas; and every 6 months, then every year for choroid plexus papillomas).